



Ariana Pharma strengthens SAB with appointment of world-leading Neurologist Jacques Touchon

Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading AI-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.

Ariana is pleased to announce that Professor Jacques Touchon, a world renown neurologist, Alzheimer's Disease specialist and co-founder of the Clinical Trials on Alzheimer's Disease (CTAD) international convention has joined its scientific advisory board.

Professor Touchon will help bolster Ariana Pharma's clinical expertise in the field of CNS diseases and expand the company's collaborations internationally. He will be joining on Ariana's SAB Professor Jean Sallantin, a pioneer of French bioinformatics and former Director of the Artificial Intelligence Laboratories at the LIRMM CNRS and Dr Alain Commerçon, former Senior Research Director within the Lead Generation organization at Sanofi-Aventis.

Professor Touchon received his Medical Degree in 1979 and his specialty in Neurology in 1992 from the Medical School of Montpellier. He has been a Professor of Neurology at the Medical School University since 1990 and Dean of the School of Medicine (2000-10). In 2004, he was appointed Chief of Neurology at Montpellier University Research Hospital and was the director of the Center for Memory Resources and Research for the Languedoc-Roussillon region. In 1999 he was awarded the academic palms for his research on Alzheimer's Disease and the Pinel Prize and was also the recipient of the Légion d'Honneur in 2007. He is currently the Editor in chief of the Journal of Prevention of Alzheimer's Disease (JPAD).

Professor Jacques Touchon commented: "we are living in the most exciting period as we start to see breakthroughs in the development of drugs that fight neurodegenerative diseases such as Alzheimer's. Looking at Ariana's track record, I strongly believe that explainable Artificial Intelligence technologies as pioneered by Ariana can transform and accelerate the development of highly needed new drugs to these patients. I am excited to join the SAB alongside my renowned colleagues".

"Ariana Pharma is proud to welcome Professor Jacques Touchon to its Scientific Advisory Board. Professor Touchon will be vital in helping us align Ariana Pharma's explainable AI platform to the needs of CNS drug development and expand our existing collaborations in this space, at one of the most exciting times in the history of drug development in CNS." Commented **Mohammad Afshar, MD, Co-founder and CEO of Ariana Pharma.**

ENDS

Note to Editors

High-resolution photograph available on request.

For further information contact:

Marion Soto

Vice President, Business Development

Email: m.soto@arianapharma.com

About Ariana Pharma

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

www.arianapharma.com